Intravenous Immunoglobulin (IVIG) in Lung Transplantation

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if intravenous immunoglobulin (IVIG) can prevent bacterial infections in lung transplant patients with low serum levels of immunoglobulin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Arcasoy, Selim, M.D.; Columbia University
• Collaborators: Columbia University; Grifols Therapeutics Inc.; Grifols Therapeutics LLC
• Treatments: Antibodies; gamma-Globulins; Immunoglobulins; Immunoglobulins, Intravenous; Rho(D) Immune Globulin

Criteria

Inclusion Criteria:

• Lung transplant recipients > 3 months after transplant surgery

• Immunoglobulin G (IgG) < 500 mg/dL

• Stable medical regimen

Exclusion Criteria:

• Acute rejection

• Active infection

• Contraindication to IVIG

• Pregnancy

• Recent thrombotic event